Timing clarification: AbbVie is scheduled to report today, Friday, July 31, 2026, before the U.S. market opens, followed by an 8:00 a.m. CT earnings call—not tomorrow. The event is AbbVie’s 2Q26 earnings release and call.
AbbVie enters 2Q26 with strong operating momentum, particularly in immunology and neuroscience, and with management having already raised its 2026 revenue and EPS outlook after 1Q. The central question is less whether AbbVie delivers growth—it should—and more whether the quarter provides enough evidence that its two core post-Humira assets, Skyrizi and Rinvoq, can continue to outperform increasingly ambitious long-term expectations.
The stock closed at $257.45 on July 30, up about 2% from June 30 but off its July 29 high of $263.30. That suggests investors remain constructive but are likely focused on the quality and durability of the growth algorithm rather than simply a headline beat.
Importantly, AbbVie pre-disclosed a $291 million acquired IPR&D and milestones charge for 2Q. Therefore, the appropriate adjusted-EPS comparison is the company’s revised range of $3.57–$3.61, rather than the original $3.74–$3.78 range that excluded the new charge. The charge itself should not be interpreted as underlying operating weakness.
| Metric | 2Q26 framework |
|---|---|
| Net revenue | ~$16.7B |
| FX impact on revenue | ~0.6% favorable |
| Adjusted operating margin | ~50% |
| Original adjusted EPS guidance | $3.74–$3.78 |
| Acquired IPR&D / milestones expense pre-disclosed July 6 | $291M / $0.17 per share |
| Revised adjusted EPS guidance, including charge | $3.57–$3.61 |
| FY26 revenue outlook | ~$67.3B |
| FY26 adjusted EPS outlook, including 1H26 disclosed IPR&D charges | $13.91–$14.11 |
The pre-announced charge is a material framing item: AbbVie’s reported adjusted EPS could appear below the initial quarter guide, while still meeting the revised range. Investors should instead concentrate on revenue, franchise mix, margins excluding deal-related items, and the implications for the second half.
AbbVie’s post-Humira strategy is working commercially. In 1Q26, Skyrizi generated $4.48B of revenue, up 29% operationally, and Rinvoq generated $2.12B, up 20% operationally. Together, those assets represented nearly 44% of company revenue in the quarter.
Management’s full-year outlook calls for:
Investors will want evidence that prescription demand, especially in inflammatory bowel disease, remains strong enough to support the $21.6B full-year outlook despite competitive launches and payer pressure. Commentary on share trends in psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis will matter more than a small quarterly revenue variance.
A sustained ~20% operational growth profile—or better—would reinforce confidence in the $10.2B annual target and management’s assertion that consensus still understates the asset’s peak sales potential.
Neuroscience delivered $2.88B in 1Q revenue, up 24% operationally. It is increasingly a key offset to legacy-product erosion and an important source of earnings diversification.
Key products to monitor:
The quarter’s read-through will depend on whether AbbVie can sustain double-digit growth across migraine, psychiatry, and Parkinson’s disease. Investors should also look for an update on tavapadon, for which management had expected a U.S. regulatory decision in the third quarter. AbbVie sees Parkinson’s as a potential franchise exceeding $5B at peak when combining tavapadon, Vyalev, and related assets.
AbbVie’s oncology business was essentially flat in 1Q on a reported basis and down 3% operationally, reflecting the expected decline in Imbruvica. The company needs continued growth from Venclexta, Elahere, and Epkinly to cushion that pressure.
The near-term commercial question is whether emerging products can offset Imbruvica at a sufficient pace. The longer-term pipeline focus is on etentamig and the solid-tumor ADC portfolio, but those opportunities are not likely to be decisive for the 2Q financial print.
Aesthetics remains a smaller but sentiment-sensitive segment. Botox Cosmetic performed well in 1Q, rising 17% operationally, but Juvederm was down 3% operationally and broader filler demand remained soft. Management has described a prolonged inflation-related pressure on the consumer, rather than a sharp cyclical downturn.
For 2Q, Botox Cosmetic growth and any stabilization in fillers will be important. Persistent filler weakness would not break the overall AbbVie thesis, but it could temper consolidated growth and reinforce concern over discretionary-consumer exposure.
In June, AbbVie agreed to acquire Apogee Therapeutics for approximately $10.9B in equity value, with closing expected in 3Q26. Apogee adds a late-stage IL-13 antibody, zumilokibart (APG777), for atopic dermatitis and an IL-13/TSLP combination program for asthma.
Strategically, the deal:
On the call, investors will likely seek clarity on closing timing, financing and leverage implications, the development plan for APG777, and how Apogee fits alongside AbbVie’s internal dermatology, immunology, and respiratory pipeline.
Beyond the financial results, the call may shape expectations around several potential catalysts:
These items reinforce why AbbVie is not simply a mature-pharma earnings story: the company’s ability to translate a broad and heavily funded pipeline into new commercial franchises is increasingly central to the medium- and long-term multiple.
A constructive report would likely include:
The principal downside risks into the call are:
AbbVie’s 2Q26 report is primarily a quality-of-growth test. The company has already framed the EPS impact from 2Q IPR&D charges, reducing the importance of a superficial EPS comparison. The more meaningful issue is whether the company can demonstrate continued outperformance in Skyrizi, Rinvoq, and neuroscience while preserving confidence in its FY26 outlook and showing that its substantial business-development investment—most recently Apogee—extends the immunology growth runway beyond the current franchise.